Form 4: Vir Biotechnology Director Sells Shares to Cover Tax Obligations

Director George A. Scangos sold 10,056 shares of Vir Biotechnology stock on February 24, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• On February 24, 2025, George A. Scangos, a director of Vir Biotechnology, Inc., sold 10,056 shares of common stock.
• The sale was executed at a price of $9.4534 per share.
• The transaction was an automatic sale to cover the issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
• Following the transaction, Scangos directly owns 698,239 shares.
• Scangos also indirectly owns a total of 3,145,289 shares through various trusts.

Sentiment

Score: 5

Explanation: This is a neutral event. The sale was to cover tax obligations, which is a common and expected practice. It doesn't necessarily indicate a negative outlook on the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge sentiment and potential future stock performance.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis, with services like InsiderScore and OpenInsider providing data and analytics on insider trading activity.
• Comparing the volume and frequency of insider sales at Vir Biotechnology to those of its peers (e.g., Gilead Sciences, Regeneron) can provide insights into management's confidence in the company's prospects.
• A single sale to cover tax obligations is generally viewed differently than a series of discretionary sales, which might signal a change in sentiment.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholders due to the slight dilution of equity.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates